Alan J. Lewis, PhD

Chairman of the Board

Karl MettingerDr. Lewis has 40 years’ experience as an executive in the life science industry. He spent 15 years at the pharmaceutical company Wyeth-Ayerst, where he was Vice President of Research, leading 550 scientists in translational research efforts including areas of diabetes, CNS, cardiovascular, inflammatory, allergy and bone metabolism diseases. He subsequently became CEO of Signal Pharmaceuticals, a drug development company that he successfully merged with Celgene and became President of Celgene’s research division in San Diego. After this success, Dr. Lewis became CEO of Novocell, Inc. (Viacyte), a diabetes stem cell company, and helped raise $27 million. He subsequently became CEO of the Juvenile Diabetes Research Foundation, the largest funding body in the world for diabetes research, which in 2010 reported revenues of $180 million. He was CEO of Ambit (acquired by Daiichi) and helped the company raise $45 million. Most recently he was the CEO of MediStem Inc., a San Diego based regenerative medicine company acquired by Intrexon (XON) in 2014. He is currently the President and CEO of DiaVacs Inc., San Diego. Dr. Lewis earned his PhD from University of Wales, Cardiff and was a research fellow at University of Guelph, Canada and a research fellow at Yale School of Medicine. He is the author of 120 manuscripts and the editor of 7 books.


Karl L. Mettinger, MD, PhD

Co-Founder, President and CEO

Karl MettingerDr. Mettinger has more than 30 years of experience as an executive in the life science industry, and has been involved with the successful development of new therapeutics, including a number of oncology, hematology, cardiovascular and CNS drugs and biologic products approved by the U.S. Food and Drug Administration, the European Medicines Agency, and other regulatory agencies worldwide. Dr. Mettinger is the Principal and Founder of Progressive Clinical partners and helped accelerate and facilitate approvals of a novel oral breakthrough therapy in lymphoma and leukemia, leading to the USD21B market cap and acquisition. He was also a consultant to Philantropist/Investor Edward Bosarge (Capital Technologies, Houston and Tissue Genesis LLC, Honolulu) helping establish a franchise in cellular therapeutics/Regenerative Medicine. He served as Medical Director of Hematology and as Deputy General Manager of the cardiovascular business unit, of Kabi (Pharmacia, now part of Pfizer), in Sweden, as Medical Director/Executive Director at IVAX Corporation (acquired by Teva Pharmaceutical Industries Ltd., NASDAQ:TEVA); Chief Medical Officer/Senior Vice President at SuperGen, (Astex, acquired by Otsuka); Chief Medical Officer at Oncolytics Biotech Inc, AB (NASDAQ: ONCY; TSX: ONC); co-founder and past President of the Swedish Stroke Society, a 10,000-member stroke research and patient support organization. Dr. Mettinger received his M.D. from the University of Lund in Sweden and his Ph.D. in Hematology/Neurology from, and is a former Associate Professor of, the Karolinska Institutet/Karolinska University Hospital in Stockholm.


Brian Lundstrom, M.Sc., MBA


Brian LundstromBrian Lundstrom has more than 30 years’ experience as an executive in the life science industry. He started his career in 1987 with product and clinical development for Novo Nordisk in Denmark. In 1993, the company transferred him to Seattle, WA, where he became head of business development and member of the executive management team of the company’s US R&D unit. He was subsequently VP, Corporate Development, for UCB in Seattle, WA, and VP, Business Development, for SangStat in Fremont, CA. After in 2003-2004 leading the $600M sale of SangStat and integration into Genzyme, he joined Californian-Swedish neuroscience company ACADIA in San Diego, CA, as SVP, Business Development. In 2009, Mr. Lundstrom became President of International Stem Cell Corporation (ISCO) in Carlsbad, CA with responsibility for public representation and financing and international collaborations until acquisition by a Russian entity. In late 2011, Mr. Lundstrom joined other ex-SangStat executives as CBO of Open Monoclonal Antibody (OMT) in Palo Alto, CA, and lead this company to market leadership and profitability in human antibody discovery platforms. OMT was sold to Ligand in early 2016 for $178M and Mr. Lundstrom stayed on as the biopharmaceutical royalty company’s head of business development. Mr. Lundstrom is also director and acting CBO for Hinge Bio. Mr. Lundstrom holds a M.Sc. in immunology and molecular biology and MBA equivalent degree in international management and finance.


Sven Andréasson, MSc


Kent PerssonSven Andréasson has more than 30 years’ experience as an executive in the life science industry. He started his career at Kabi, Stockholm, where he became CEO for the German, UK and Belgian subsidiaries. He subsequently became head of the Biopharmaceutical division responsible for human growth hormones, blood plasma products, and LMW heparin/thrombolytic cardiovascular products. After the acquisition of Pharmacia in 1989 he became President of Pharmacia International in Brussels, Belgium and later Pharmacia SA, Paris, France (today part of Pfizer). From 1999 he served for nine years as the President and CEO of Active Biotech, Lund Sweden, a publicly traded company developing innovative products for autoimmune diseases including multiple sclerosis (partnered with TEVA) and for various cancers. He subsequently became CEO of Beta-Cell NV, in Brussels, a company developing cell-based treatments for diabetes. In February 2012 he became CEO of Isconova AB, a vaccine development company acquired by Novavax Inc, Rockville, MD, where he is Senior VP, Corporate Development. Sven Andréasson has an MSc in business administration and finance from the Stockholm School of Economics..


Brad Thompson, PhD, Director


Brad ThompsonDr. Thompson, Ph.D., CEO and Co-Founder of Kickshaw Ventures, is an experienced and highly respected biotechnology professional for more than 30 years. Most recently he served as Director and the Chairman of BIOTECanada, and as Executive Chairman, CEO and President of Oncolytic Biotech Inc. He started his career in biotech as Head of Biotechnology at The Alberta Research Council where he was responsible for GMP manufacturing for biologics as well held a variety of other positions from 1983 to May 1994. He served, amongst others, as a Director of Signal Gene, Paladin Labs Inc., Transition Therapeutics and Immunovaccine, Inc., and is a current board member of Aptose Biosciences Inc. He received a B.Sc. from the University of Alberta and a Ph.D. in microbiology and immunology from the University of Western Ontario.


Kent Persson, PhD

Co-Founder, Director, and Scientific Advisor

Kent PerssonDr. Persson is an experienced cell and molecular biologist with over 14 years research expertise in genomics and molecular-cellular biology. He holds a Ph.D. in Molecular Biology from Umeå University in Sweden and did a Postdoctoral Fellowship in gene expression research at the University of California San Francisco. Currently, Dr. Persson is a Senior Scientist/Project Manager with the Biopharmaceutical Division of Octapharma AB, Stockholm, Sweden, where he oversees Cell and Molecular Biology and manages process analysis development, introducing new molecular biology techniques including development of technologies in cell culturing, recombinant protein production, and molecular biological IND filings. Previously, Dr. Persson was a Senior Scientist in the Gene Expression Division of Bio-Rad Laboratories in California, participated in research and development of gene expression tools and led technical training in genetic analysis.


Daniel Quintero

General Counsel, Corporate Secretary

Kent Persson Daniel Quintero has a long and distinguished career in Silicon Valley and the Bay area. He is a Founding Partner and Managing Partner of Prometheus Partners LLP, a diverse group of accomplished former Big Law Partners and Executive In House counsel committed to supporting innovation.  Mr. Quintero was previously the General Counsel and Corporate Secretary for Sony Optiarc America Inc., where he concurrently served as Senior Managing Counsel and Director for Sony Electronics Inc. and managed Sony's Silicon Valley law department operations. His responsibilities included advising executive management and the board of directors of a multi-national corporation, and negotiating and structuring multi-million and multi-billion dollar engagements. Mr. Quintero is largely well respected for his views on innovation and technology and was named one of California’s Top 20 General Counsel by the Daily Journal in 2012. . Mr. Quintero received his undergraduate degree from the University of San Francisco (USF), and received his law degree from Berkeley Law (Boalt Hall), University of California at Berkeley.